| | Identification | Back Directory |  | [Name] 
 Methanesulfonamide, N-[2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-, hydrochloride (1:1)
 |  | [CAS] 
 1784253-05-9
 |  | [Synonyms] 
 CZC-54252 HCl
 Methanesulfonamide, N-[2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-, hydrochloride (1:1)
 CZC 54252,CZC54252 hydrochloride,injury,inhibit,LRRK2,CZC54252,CZC-54252,neuronal,Leucine-rich repeat kinase 2,neuroprotective,Inhibitor,CZC 54252 hydrochloride,LRRK2-G2019S
 |  | [Molecular Formula] 
 C22H26Cl2N6O4S
 |  | [MOL File] 
 1784253-05-9.mol
 |  | [Molecular Weight] 
 541.45
 | 
 | Chemical Properties | Back Directory |  | [storage temp. ] 
 -20°
 |  | [solubility ] 
 Soluble in DMSO (up to 50 mg/ml).
 |  | [form ] 
 solid
 |  | [color ] 
 Off-white
 |  | [Stability:] 
 Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months.
 | 
 | Hazard Information | Back Directory |  | [Description] 
 CZC-54252 HCl (1784253-05-9) is a novel, potent and selective inhibitor of the leucine-rich repeat kinase-2 (LRRK2), IC50 = 1.28 nM. Also inhibits G2019S mutant LRRK2, IC50 = 1.85 nM.1?CZC-54252 attenuates the neuronal damage elicited by the action of LRRK2 G2019S mutant in primary human neurons (EC50 = 1 nM).1 The G2019S mutant is a common mutation found in familial Parkinson’s disease patients.2?Cell permeable.
 |  | [Uses] 
 CZC-54252 hydrochloride is a potent and selective LRRK2 inhibitor with IC50s of 1.28 nM and 1.85 nM for wild-type and G2019S LRRK2, respectively. G2019S LRRK2-induced human neuronal injury is attenuated by CZC-54252 hydrochloride with an EC50 of ~1 nM.CZC-54252 hydrochloride has a neuroprotective activity[1].
 |  | [References] 
 1) Ramsden et al. (2011), Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson’s disease-related toxicity in human neurons; ACS Chem. Biol., 6 102
2) Kramer et al. (2012), Small molecule kinase inhibitors for LRRK2 and their application to Parkinson’s disease models; ACS Chem. Neurosci., 3 151
 | 
 | 
                    
                        
                            | Company Name: | InvivoChem |  
                            | Tel: | 13549236410 |  
                            | Website: | https://www.invivochem.cn/ |  |